ArticlePharmaceutics2021

ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.

Wenlong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.